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Abstract
Objectives: The United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), the
main primary healthcare provider for 4.9 million Palestinian refugees, spent USD18.3 million on essential medicines
dispensed free-of-charge through clinics in five areas of operation (‘fields’): Gaza, Jordan, Lebanon, Syria, and the
West Bank (2010). Faced with budget contraints and an increasing demand for medicines to treat chronic
conditions, the objective of our study was to assess UNRWA’s medicine procurement prices to see if savings
could be possible.
Methods: In July 2011, data was collected from UNRWA headquarters in Jordan. Price analyses focused on the
top 80 medicines by value, accounting for 93% of pharmaceutical expenditure from the General Fund, with
comparisons to international, regional and national references. Prices were also compared for the few medicines
procured both through UNRWA’s central tender (centrally) and by the fields directly (locally).
Results: Central procurement prices did not differ markedly from reference prices: median ratios of UNRWA prices
to Management Sciences for Health’s International Drug Price Indicator Guide, Jordan’s Joint Procurement
Department, Gulf Cooperation Council, and IDA Foundation bulk packs were 0.99, 1.00, 0.98 and 1.12 respectively.
Applying the lowest comparator price to five comparatively higher priced medicines would yield savings of USD1.4
million. Local procurements were generally less cost-effective than central tender procurement, with notable
differences across fields and medicines.
Conclusions: Overall, UNRWA’s procurement prices were competitive despite the relatively small quantities
procured. Regular monitoring of procurement prices and quantities is needed in order to make informed decisions.
Our evaluation also underscores the heavy burden of antidiabetic medicines and antimicrobials on UNRWA
procurement expenditure.
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The United Nations Relief and Works Agency for
Palestine Refugees in the Near East (UNRWA), whose
headquarters are in Amman Jordan, provides assistance,
protection and advocacy for 4.9 million Palestine refu-
gees living in the five areas (‘fields’) of its operation:
Jordan, Lebanon, Syria, and the Gaza Strip and West
Bank, which are occupied Palestinian territory. Providing
primary health care is a key component of this assist-
ance, which has resulted in improvements in the health
status of refugees over the last 60 years, in particular in
the reduction of maternal and child mortality. This has
been achieved despite poor living conditions and high
levels of unemployment of refugees, and political in-
stability and frequent conflict in the region.
Medicines are supplied free-of-charge to refugees
through 137 primary healthcare centres (PHC) across the
five fields, and in one hospital in the West Bank. In 2010,
pharmaceutical expenditure was US$18.31 million. Of
this, $15.4 million was from UNRWA’sG e n e r a lF u n d ;t h e
balance is donations and medicines purchased in emer-
gency situations [1]. The top 10 medicines procured in
2010 by value had a total expenditure of US$6.7 million
[2]. Of these, three were used to treat diabetes and five
were antimicrobials (see Table 1). Expenditure was highest
for neutral sol./isophane 30/70 human insulin at approxi-
mately $1.5 million (9.6% of General Fund expenditure on
medicines). Most medicines are procured via a central
open tender, although some medicines are procured by
field staff directly. Suppliers are required to be pre-
qualified [3]. The lowest bid amidst those technically
accepted is awarded the tender (assuming supply and
other aspects are satisfactory). Prices are not negotiated
although UNRWA can terminate a contract if they can
get a lower price. About 85% of awarded contracts are
longer term (three years).
A number of factors are contributing to an increased
demand for health care services including an increase in
the refugee population, a doubling of the elderly po-
pulation in the last 30 years, and an epidemiological
transition from acute to chronic diseases, in particular
diabetes and cardiovascular disease. Chronic diseases
account for 70-80% of deaths among refugees, and over
the last decade the number of patients with hypertension
and/or diabetes increased by 134% [1]. Coupled with in-
creasing demand, UNRWA was facing a funding deficit,
estimated to be $63 million in 2011 (from a total budget
of $500 million).
Faced with the challenge of providing health services
in an environment of growing need and resource con-
straints, UNRWA initiated a health reform process in
2009 which included various pharmaceutical reviews.
Their Essential Medicines List (termed the ‘Rational
Drug List’ by UNRWA) was revised in 2010. Reviews of
the quantification process, inventory management, and
the use of medicines in PHC’s are also included in the
reform process.
The objective of our study was to assess UNRWA’s
medicine procurement prices and processes. In particu-
lar, recent procurement prices would be compared with
those from international, regional and national sources,
with recommendation on where savings might be pos-
sible. The methodology differed from that reported in
nine medicine price surveys undertaken in the World
Health Organization’s Eastern Mediterranean Region
from 2004 to 2006, where only a single comparator was
used [4].
The challenges faced by UNRWA in procuring rela-
tively small quantities of medicines in a difficult environ-
ment, with differing situations in the five fields where
medicines would be delivered, would create an ex-
pectation that prices would be higher than in less
Table 1 Top 10 medicines by expenditure in 2010, central and local procurements
Medicine, strength, dose form Therapeutic group Expenditure in USD Expenditure as % of general fund
expenditure on medicines
Neutral sol./isophane 30/70 human insulin 100 IU/ml 10 ml vial Antidiabetic medicine $ 1,478,122 9.6%
Amoxicillin+clavulanic acid 500+125 mg tab Antimicrobial $ 973,521 6.3%
Amoxicillin 250 mg/5 ml suspension Antimicrobial $ 716,602 4.7%
Enalapril maleate 10 mg tab Antihypertensive $ 661,834 4.3%
Amoxicillin 500 mg cap Antimicrobial $ 606,882 4.0%
Amoxicillin+clavulanic acid 250+62 mg/5 ml suspension Antimicrobial $ 567,409 3.7%
Cephalexin 500 mg cap Antimicrobial $ 473,402 3.1%
Metformin HCL 500 mg tab Antidiabetic medicine $ 446,482 2.9%
Gliclazide 80 mg tab Antidiabetic medicine $ 418,102 2.7%
Paracetamol 250 mg/5 ml suspension Antipyretic, analgesic $ 411,496 2.7%
Total $ 6,753,853 44%
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in this article (but not the review of the procurement pro-
cesses). Findings from both analyses can be found in the
report published by UNRWA entitled Medicine pro-
curement prices and processes in the United Nations
Relief and Works Agency for Palestine Refugees in the Near
East (UNRWA) (http://www.unrwa.org/sites/default/files/
201210212936.pdf).
Methods
In July 2011, data was collected from the health, pro-
curement and finance departments at UNRWA head-
quarters. Prices and quantities procured in 2010, from
UNRWA’s General Fund, were extracted from their Pro-
curement Inventory Management System (PIMS) data-
base and analysed [2].
In total 80 medicines were initially selected (out of a total
of 143 medicines and vaccines procured), each strength-
and dose-form specific, equating to the top 80 medicines
b yv a l u eb u te x c l u d i n gaf e wp r o d u c t sm o r es p e c i f i ct o
UNRWA (e.g. metacresolsulphonic acid-formaldehyde pes-
saries), and where comparing products with identical active
ingredients and strengths (e.g. multivitamin tablets) could
be challenging. The medicines in the analysis accounted
for 93% of UNRWA’s pharmaceutical expenditure from the
General Fund. The prices included freight and insurance,
and any discounts were deducted. For medicines where
multiple products were procured, the median price
(unweighted) was used.
In the main analysis only 2010 central tender prices
were included, thereby reducing the number of medi-
cines from 80 to 77. A separate analysis was undertaken
comparing prices for medicines procured in 2010 both
through the central tender process (centrally) and those
procured by each field (locally). Initially this second ana-
lysis was limited to the 80 selected medicines but, as the
dataset was small, the analysis was extended to all medi-
cines procured both centrally and locally.
UNRWA’s procurement prices were compared with
2010 prices from Management Sciences for Health’s
International Drug Price Indicator Guide (MSH) [5], the
Gulf Cooperation Council (GCC) [6], Jordan’s Joint Pro-
curement Department (JPD) [7], and the IDA Foundation
(IDA) [8] - see Table 2.
For a few liquid preparations, GCC permits supply
within a narrow pack size eg. chlorphenamine 2 mg/5 ml
oral solution can be supplied in bottles of 100 - 120 ml.
Where the actual pack size supplied was unknown, the
analysis was based on the UNRWA procurement unit i.e.
100 ml for chlorphenamine. Comparators prices were ex-
cluded in the analysis for pack sizes substantially different
to those procured by UNRWA. Prices were included for
four medicines where a comparator was found to have a
slightly different strength e.g. benzylpencillin benzathine
GCC price was for 1MIU/vial whereas the others were
1.2MIU/vial.
Prices were expressed as a ratio of the UNRWA unit
price in USD to the comparator unit price in USD. The
ratio is thus expression of how much greater or less the
UNRWA price is than the comparator price.
Two sensitivity analyses were undertaken to identify
potential savings on expenditure based on the quantities
procured by UNRWA in 2010 (1) if all matched me-
dicines were procured at JPD, GCC, and IDA prices; and
(2) if selected medicines were procured at JPD, GCC,
and IDA prices. Three approaches were used to identify
individual medicines that offered significant savings
potential based on comparator prices: medicines where po-
tential annual savings exceeded US$100,000, UNRWA’st o p
10 medicines by expenditure, and antidiabetes medicines.
Results
There was little difference between UNRWA procure-
ment prices and comparator prices across the medicines
where there were matches. Overall UNRWA prices were
1% and 2% lower than MSH and GCC prices respec-
tively, the same as the prices paid by JPD, and 12%
higher than IDA bulk prices (see Table 3).
There were some wide price variations for individual
medicines. UNRWA prices were more than three times
Table 2 Price comparators
Comparator Description
Management Sciences for Health’s (MSH) International Drug
Price Indicator Guide 2010 http://erc.msh.org
Ex-factory prices offered to low- and middle-income countries by different suppliers.
Median supplier prices were used (or median buyer prices where supplier prices were
unavailable) plus 15% for freight and insurance.
Jordan’s Joint Procurement Department (JPD) 2010 tender
prices www.jpd.gov.jo
Pooled procurement for the Ministry of Health, Royal Medical Services, Jordan
University Hospital, King Abdullah University Hospital, King Hussein Cancer Centre and
the Prince Hamza Hospital. Prices include freight, insurance, any clearance costs and
transport to warehouses in Jordan.
Gulf Cooperation Council (GCC) 2010 tender prices Pooled procurement for the United Arab Emirates, Bahrain, Kingdom of Saudi Arabia,
Oman, Qatar Kuwait, and more recently Yemen. Prices include freight, insurance, any
clearance costs and transport to warehouses in each country.
IDA Foundation 2010 prices for bulk packs www.ida.nl Not-for-profit supplier of medicines to low- and middle-income countries. Prices
include 1.5% handling fee (for orders over Є5000) plus 15% for freight and insurance.
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nicillin benzathine injection (20.9, 7.6 and 4.0 times the
MSH, GCC and IDA price respectively), acetylsalicyclic
acid 500 mg tablets (9.9 and 9.6 times the IDA and
MSH price respectively), chlorphenamine 4 mg tablets
(5.2, 4.6 and 3.3 times the MSH, IDA and GCC price re-
spectively), and digoxin 0.25 mg tablets (3.4 times the
MSH price). Conversely, UNRWA prices were lower
than comparator prices for some medicines such as
miconazole 2% oral gel (92% lower than the MSH price),
salbutamol 0.5% respiratory solution (90% and 69% lo-
wer than the MSH and IDA price respectively), and
indomethacin 100 mg suppositories (85% and75% below
the GCC and MSH price respectively).
High prices of individual medicines compared to com-
parator prices indicates there may be opportunities for
UNRWA to buy at lower prices and hence reduce expen-
diture. Taking into account the quantities of individual
medicines procured by UNRWA in 2010, buying all or
selected medicines at JPD, GCC and IDA prices was
considered. If UNRWA were able to join the JPD tender or
GCC tender, overall expenditure would increase by ap-
proximately US$360,000 (for 56 medicines) and US$ 1.88
million (for 62 medicines) respectively assuming no re-
duction in tender prices due to the increased quantity pro-
cured. Buying the 52 matched medicines from IDA would
increase expenditure by approximately US$125,000. Com-
petitive negotiation or joining the JPD or GCC tender for a
limited list of medicines could be considered. As shown in
Table 4, human 30/70 insulin offered the greatest savings if
procured at the GCC price ($467,624), followed by amoxi-
cillin+clavulanic acid tablets, benzlpenicillin benzathine
vials, gliclazide and azithromycin suspension. If these five
medicines could be procured at the lowest comparator
prices, UNRWA would reduce annual expenditure by $1.4
million.
An analysis of prices of medicines procured in 2010 via
UNRWA’s central tender (centrally) and directly by each
field (locally) showed that overall Syria was paying 20%
less when procuring locally (30 medicines), Lebanon was
paying 83% more (11 medicines), and West Bank was
paying 128% more (18 medicines). Insufficient data was
available for Jordan and Gaza to draw any conclusions.
Discussion
In contrast to medicine price surveys undertaken using
the World Health Organization (WHO)/Health Action
International (HAI) methodology [9] in which a single
comparator price (Management Sciences for Health) is
used, this study utilized four reference prices. These were
prices from a neighbouring and host country (Jordan’s
Joint Procurement Department, JPD), a regional procure-
ment organization (Gulf Cooperation Council, GCC), a
non-profit international supplier (IDA Foundation, IDA),
and an international price indicator guide (Management
Sciences for Health, MSH) that consolidates prices from
mostly non-profit suppliers and national government pro-
curement bodies. By comparing to such a range of com-
parators we are able to ask the “what if” question in a
more comprehensive way and a more detailed manner
than if we had used a single comparator price.
Overall UNRWA was procuring medicines efficiently
when the prices of centrally procured medicines were
compared with MSH, JPD, GCC and IDA comparator
prices. This is despite relatively small order quantities
and the political challenges of procurement and delivery
in this challenging environment.
An analysis by Cameron et al. showed that public sector
procurement prices for 15 medicines (lowest-priced ge-
nerics) in 39 predominantly low- and middle-income
countries were, on average, 1.11 times MSH prices [10].
While most countries were procuring medicines at com-
petitive prices, some countries were paying over three
times MSH prices. In the WHO EMRO/HAI report of
findings from nine countries in the Eastern Mediterranean
Table 3 Summary of ratios of UNRWA central tender
prices to MSH, JPD, GCC and IDA prices
MSH JPD GCC IDA
Median ratio UNRWA price to comparator price 0.99 1.00 0.98 1.12
25th percentile ratio 0.66 0.73 0.59 0.76
75th percentile ratio 1.49 1.47 1.39 1.57
Maximum ratio 20.93 2.96 7.55 9.94
Minimum ratio 0.08 0.23 0.14 0.23
Number of medicines 68 56 62 52
Table 4 Medicines offering the greatest potential savings (to UNRWA central tender prices)
Medicine Therapeutic group Comparator Potential annual savings in USD
Neutral sol./isophane insulin 30/70 100 IU/ml 10 ml vial Antidiabetic GCC price $ 467,624
Amoxicillin+clavulanic acid 500+125 mg tab Antimicrobial GCC price $ 393,109
Benzylpenicillin benzathine 1/1.2MIU vial Antimicrobial GCC price $ 243,822
Gliclazide 80 mg tab Antidiabetic JPD price $ 210,907
Azithromycin 200 mg/5 ml suspension Antimicrobial JPD price $ 144,489
Total $ 1,459,951 (9.5% of General Fund
expenditure on medicines)
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lowest-priced generics where less than MSH prices in four
countries (Jordan, Yemen, Pakistan and Jordan) and be-
tween 1 and 2 times MSH prices in five countries (Kuwait,
Lebanon, Syria, Tunisia and Morocco) [4]. Our study
showed that across a larger sample of 68 medicines, over-
all UNRWA was paying 0.99 times MSH prices hence
achieving more competitive prices than many countries.
Based on the quantities procured by UNRWA, expend-
iture would increase if UNRWA procured the medicines
in this analysis through the JPD or GCC tenders, or from
IDA. However, savings are possible if some individual
medicines were procured at lower comparator prices. We
identified five medicines (one insulin, one oral antidiabetic
medicine, and three beta-lactam antimicrobials) where
substantial savings could be possible if they were procured
at lowest comparator prices. In view of the heavy burden
of antidiabetic medicines and antimicrobials on UNRWA
medicine expenditure, pursuing options such as competi-
tive negotiation with suppliers or joining the JPD and/or
GCC tenders for these few medicines is recommended.
Another option would be to increase the number of
UNRWA pre-qualified suppliers to attract more tender
bids. At the time of the study, UNRWA had pre-qualified
101 suppliers, the vast majority of whom were from
Europe and Jordan (few were from Asia). On average,
three tender bids are received for each medicine. JPD re-
ceives an average of six bids per medicine, and the Jordan
Food and Drug Authority has more than 500 suppliers of
medicines (although the Jordan market is not as restricted
as UNRWA’s). UNRWA should review the pre-qualified
suppliers in Jordan and other host countries, as well as in
other countries in the region, to identify potential new
suppliers. Consideration should particularly be given to
identifying potential suppliers from outside the region
who supply quality-assured products and are likely to have
competitive prices.
With budget constraints and a dynamic pharmaceuticals
market, there is a need to regularly monitor prices and
quantities in order to make informed decisions on the
optimum procurement process, bids, contract termination
etc. Sustainability is needed so limiting the review to the
top 20 medicines by expenditure is recommended. Consi-
deration of useful comparators is needed; they should be a
mix of regional and international sources. Forging links
with national medicine procurement departments should
facilitate the data collection process. As well, the World
Health Organization’s Regional Office for the Eastern
Mediterranean should be encouraged to establish a re-
gional procurement price database that UNRWA could
both contribute to and access prices paid by countries in
the region. Such a database has been developed in the
World Health Organization’s Regional Office for the
Western Pacific [11].
This study had a number of limitations including the
limited number of comparators for the regional price
comparisons. Prices were unsuccessfully sought from
Lebanon, Syria and Egypt. No adjustments were made
for additional freight charges and documentation costs
often required for medicines supplied to Gaza and the
West Bank. It must also be remembered that any savings
are only potential. Competitive negotiation may not re-
sult in the prices of the comparators, and joining others
tenders may not be possible. In addition, price is not the
only consideration when procuring medicines. Processes
are needed that ensure quantification is based on need,
the medicines procured are of assured quality, and there
are no interruptions in supply.
Policies that target preventable risk factors for diabetes,
cardiovascular disease and other conditions are important
to reduce morbidity and the need for pharmaceutical
treatment. When medicines are needed, strategies to en-
sure they are appropriately prescribed and dispensed by
health professionals, and appropriately used by patients,
are also important.
Conclusion
UNRWA is able to procure medicines in relatively small
quantities at competitive prices demonstrating that irre-
spective of the challenges faced, good procurement prac-
tices result in prices that are close to international
norms. With budget constraints and a dynamic market,
there is a need to regularly monitor procurement prices
and quantities in order to make informed decisions.
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